Latest From LuxCath LLC
HRS 2018 Wrap-Up: Tendril Lead Failures; Metaanalysis Of Contact-Force Catheter; LuxCath's OmniView; More Micra Results
The 2018 Heart Rhythm Society scientific sessions in Boston covered a variety of presentations of new electrophysiology clinical data, including a report on the failure of St. Jude's Tendril leads, a meta-analysis of contact-force catheters for atrial-fibrillation ablation, and new data on Medtronic's Micra leadless pacemaker.
The market for atrial fibrillation catheter ablation devices continues to grow even as the field wrestles with basic questions and as new study results may dampen enthusiasm for some technologies. Though strategics dominate this sector, innovators with new approaches to ablation and mapping hope to help resolve unknowns and take a piece of this vast and underpenetrated market.
Brief profiles of these recently formed companies: ABK Biomedical, LuxCath, Quantamerix, SkelRegen, Thesan Pharmaceuticals, and Ziarco Pharma.
- Monitoring Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- LuxCath LLC
- Senior Management
Omar Amirana, MD, CEO
Terry Ransbury, CTO
- Contact Info
Phone: (617) 419-1800
100 High St.
Boston, MA 02110
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.